Trial Profile
IPI-926 Extension Protocol for Continuation of IPI-926 Treatment in Patients Experiencing Clinical Benefit While Enrolled in an IPI-926 Protocol
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Nov 2012
Price :
$35
*
At a glance
- Drugs Patidegib (Primary)
- Indications Basal cell cancer
- Focus Adverse reactions
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 20 Jun 2012 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.